US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?
Executive Summary
Lawmakers inquire about expanding pre-submission meetings to include non-complex priority ANDAs, suggesting it could be another way to help deal with drug pricing issues.
You may also be interested in...
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.
Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says
Chair of the House Energy and Commerce Health Subcommittee expects BsUFA II also to be judged on FDA's review process predictability.